(Q30387154)

English

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive c

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive c (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Althaf I Hussain

1

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Melissa Cordeiro

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Elizabeth Sevilla

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Jonathan Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

language of work or name

0 references

publication date

20 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

3848-3855

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

describes a project that uses

0 references

Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

NEW technologies for meeting the global demand for pandemic influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

The annual production cycle for influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Cell-based influenza vaccines: progress to date.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Effectiveness of school-based influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Use of MDCK cells for production of live attenuated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Influenza A virus-induced apoptosis in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine release

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

The growth of attenuated influenza vaccine donor strains in continuous cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Development of a novel recombinant influenza vaccine in insect cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Plant-expressed HA as a seasonal influenza vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

Sensitivity of NCI-H292 human lung mucoepidermoid cells for respiratory and other human viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

based on heuristic

inferred from DOI database lookup

African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.03.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended composition of influenza virus vaccines for use in the 2006-2007 influenza season

1 reference

https://pubmed.ncbi.nlm.nih.gov/20307595

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2010.03.005

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

release_n7zkfwlltvezzdfmxdhz5q5yju

1 reference

https://api.fatcat.wiki/v0/release/n7zkfwlltvezzdfmxdhz5q5yju

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

https://api.fatcat.wiki/v0/release/n7zkfwlltvezzdfmxdhz5q5yju

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30387154&oldid=1842325508"